| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 免疫系统用药(元) | 169,446,937.34 | 100,824,930.92 | 358,200,302.12 | 185,458,599.80 |
| 神经系统用药(元) | 55,791,757.17 | 34,971,571.57 | 76,862,005.38 | 38,114,651.13 |
| 心脑血管用药(元) | 247,503,871.90 | 129,954,762.53 | 294,141,952.26 | 155,632,651.30 |
| 其他主营业务(元) | - | - | - | 4,137,006.84 |
| 其他(元) | 3,827,015.30 | 6,286,499.07 | 5,342,592.83 | 4,137,006.84 |
| 营业成本(元) | ||||
| 免疫系统用药(元) | 60,132,284.65 | 28,147,037.78 | 83,635,972.48 | 42,452,077.93 |
| 神经系统用药(元) | 27,702,405.95 | 16,616,236.38 | 24,993,724.88 | 14,644,862.52 |
| 心脑血管用药(元) | 50,245,594.60 | 28,648,301.58 | 58,886,440.93 | 30,109,456.74 |
| 其他主营业务(元) | - | - | - | 1,605,715.66 |
| 其他(元) | 2,859,029.13 | 3,014,722.60 | 4,091,404.02 | 1,605,715.66 |
| 毛利(元) | ||||
| 免疫系统用药(元) | 109,314,652.69 | 72,677,893.14 | 274,564,329.64 | 143,006,521.87 |
| 神经系统用药(元) | 28,089,351.22 | 18,355,335.19 | 51,868,280.50 | 23,469,788.61 |
| 心脑血管用药(元) | 197,258,277.30 | 101,306,460.95 | 235,255,511.33 | 125,523,194.56 |
| 其他主营业务(元) | - | - | - | 2,531,291.18 |
| 其他(元) | 967,986.17 | 3,271,776.47 | 1,251,188.81 | 2,531,291.18 |
| 毛利率(%) | ||||
| 免疫系统用药(%) | 64.51 | 72.08 | 76.65 | 77.11 |
| 神经系统用药(%) | 50.35 | 52.49 | 67.48 | 61.58 |
| 心脑血管用药(%) | 79.70 | 77.96 | 79.98 | 80.65 |
| 其他主营业务(%) | - | - | - | 61.19 |
| 其他(%) | 25.29 | 52.04 | 23.42 | 61.19 |
| 收入构成(%) | ||||
| 免疫系统用药(%) | 35.56 | 37.06 | 48.76 | 47.86 |
| 神经系统用药(%) | 11.71 | 12.86 | 10.46 | 9.84 |
| 心脑血管用药(%) | 51.93 | 47.77 | 40.04 | 40.17 |
| 其他主营业务(%) | - | - | - | 1.07 |
| 其他(%) | 0.80 | 2.31 | 0.73 | 1.07 |
| 毛利构成(%) | ||||
| 免疫系统用药(%) | 32.57 | 37.15 | 48.77 | 48.14 |
| 神经系统用药(%) | 8.37 | 9.38 | 9.21 | 7.90 |
| 心脑血管用药(%) | 58.77 | 51.79 | 41.79 | 42.25 |
| 其他主营业务(%) | - | - | - | 0.85 |
| 其他(%) | 0.29 | 1.67 | 0.22 | 0.85 |